IMMUTEP LIMITED - AMER

Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

31 Mar 2023 05:00:00 By Nasdaq GlobeNewswire

Immutep Announces Expansion of Triple Combination Therapy in 1st Line Non-Small Cell Lung Cancer

30 Mar 2023 05:00:00 By Nasdaq GlobeNewswire

Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

23 Mar 2023 05:00:00 By Nasdaq GlobeNewswire

Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

14 Mar 2023 05:00:01 By Nasdaq GlobeNewswire

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

06 Feb 2023 05:00:01 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

30 Jan 2023 05:00:01 By Nasdaq GlobeNewswire

Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer

04 Jan 2023 05:00:01 By Nasdaq GlobeNewswire

Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer

23 Dec 2022 05:00:00 By Nasdaq GlobeNewswire

Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha

08 Dec 2022 05:00:01 By Nasdaq GlobeNewswire

Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

06 Dec 2022 05:00:01 By Nasdaq GlobeNewswire

Immutep to Participate in The JMP Securities Hematology and Oncology Summit

02 Dec 2022 05:00:00 By Nasdaq GlobeNewswire

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

29 Nov 2022 05:00:01 By Nasdaq GlobeNewswire

Immutep Receives Australian R&D Tax Incentive

14 Nov 2022 05:00:01 By Nasdaq GlobeNewswire

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

10 Nov 2022 08:10:00 By Nasdaq GlobeNewswire

Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022

10 Nov 2022 06:00:02 By Nasdaq GlobeNewswire

Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

09 Nov 2022 05:00:01 By Nasdaq GlobeNewswire

Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference

04 Nov 2022 05:00:00 By Nasdaq GlobeNewswire

Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

02 Nov 2022 05:00:03 By Nasdaq GlobeNewswire

Immutep to Participate in Two Upcoming Investor Conferences

01 Nov 2022 16:59:04 By Nasdaq GlobeNewswire

Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

26 Oct 2022 05:00:01 By Nasdaq GlobeNewswire